Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -39.48 Thousand CAD | -102.21% |
| 2022 | 1.78 Million CAD | 9.72% |
| 2021 | 1.63 Million CAD | 126.18% |
| 2020 | -6.22 Million CAD | -19611.01% |
| 2019 | 31.91 Thousand CAD | 100.37% |
| 2018 | -8.62 Million CAD | -128.08% |
| 2017 | -3.78 Million CAD | -605.08% |
| 2016 | 748.4 Thousand CAD | 21.89% |
| 2015 | 613.98 Thousand CAD | 263.35% |
| 2014 | 168.97 Thousand CAD | 12162.63% |
| 2013 | 1378.00 CAD | 100.05% |
| 2012 | -2.63 Million CAD | -0.88% |
| 2011 | -2.61 Million CAD | -2.97% |
| 2010 | -2.53 Million CAD | -2.17% |
| 2009 | -2.48 Million CAD | 32.26% |
| 2008 | -3.66 Million CAD | -35.26% |
| 2007 | -2.71 Million CAD | -29.63% |
| 2006 | -2.09 Million CAD | -1766.6% |
| 2005 | 125.52 Thousand CAD | 779.9% |
| 2004 | 14.26 Thousand CAD | 103.92% |
| 2003 | -363.7 Thousand CAD | -623.28% |
| 2002 | 69.5 Thousand CAD | -71.17% |
| 2001 | 241.12 Thousand CAD | 153.56% |
| 2000 | -450.22 Thousand CAD | 90.42% |
| 1999 | -4.7 Million CAD | -123.81% |
| 1998 | -2.1 Million CAD | -2000.0% |
| 1997 | -100 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 246.74 Thousand CAD | -34.68% |
| 2024 Q1 | 2.45 Million CAD | 22.94% |
| 2024 Q2 | 377.73 Thousand CAD | -84.62% |
| 2023 Q2 | -169.75 Thousand CAD | 88.64% |
| 2023 FY | -39.48 Thousand CAD | -102.21% |
| 2023 Q4 | 1.99 Million CAD | 359.69% |
| 2023 Q3 | -769.1 Thousand CAD | -353.06% |
| 2023 Q1 | -1.49 Million CAD | -221.97% |
| 2022 Q3 | 444.26 Thousand CAD | -16.23% |
| 2022 Q4 | -464.08 Thousand CAD | -204.46% |
| 2022 FY | 1.78 Million CAD | 9.72% |
| 2022 Q1 | 880.77 Thousand CAD | 13.08% |
| 2022 Q2 | 530.36 Thousand CAD | -39.78% |
| 2021 Q3 | 1.51 Million CAD | 87.77% |
| 2021 FY | 1.63 Million CAD | 126.18% |
| 2021 Q1 | 130.81 Thousand CAD | 102.63% |
| 2021 Q2 | 807.46 Thousand CAD | 517.24% |
| 2021 Q4 | 778.92 Thousand CAD | -48.63% |
| 2020 Q3 | -440.23 Thousand CAD | -100.99% |
| 2020 Q2 | -219.03 Thousand CAD | 62.58% |
| 2020 FY | -6.22 Million CAD | -19611.01% |
| 2020 Q4 | -4.98 Million CAD | -1031.9% |
| 2020 Q1 | -585.26 Thousand CAD | -1098.92% |
| 2019 Q1 | -119.29 Thousand CAD | 98.54% |
| 2019 Q4 | -48.81 Thousand CAD | 74.48% |
| 2019 Q3 | -191.32 Thousand CAD | -148.89% |
| 2019 Q2 | 391.35 Thousand CAD | 428.05% |
| 2019 FY | 31.91 Thousand CAD | 100.37% |
| 2018 Q4 | -8.18 Million CAD | -854577.45% |
| 2018 Q2 | -342.5 Thousand CAD | -263.87% |
| 2018 FY | -8.62 Million CAD | -128.08% |
| 2018 Q1 | -94.12 Thousand CAD | 90.68% |
| 2018 Q3 | 958.00 CAD | 100.28% |
| 2017 Q4 | -1 Million CAD | -635.35% |
| 2017 FY | -3.78 Million CAD | -605.08% |
| 2017 Q3 | 188.64 Thousand CAD | -26.78% |
| 2017 Q2 | 257.64 Thousand CAD | 108.01% |
| 2017 Q1 | -3.21 Million CAD | -472.74% |
| 2016 Q2 | 175.94 Thousand CAD | 151.99% |
| 2016 FY | 748.4 Thousand CAD | 21.89% |
| 2016 Q1 | -338.42 Thousand CAD | -183.95% |
| 2016 Q3 | 47.95 Thousand CAD | -72.75% |
| 2016 Q4 | 862.93 Thousand CAD | 1699.53% |
| 2015 Q3 | 82.15 Thousand CAD | -35.2% |
| 2015 FY | 613.98 Thousand CAD | 263.35% |
| 2015 Q2 | 126.77 Thousand CAD | 6434.69% |
| 2015 Q1 | 1940.00 CAD | 100.55% |
| 2015 Q4 | 403.11 Thousand CAD | 390.68% |
| 2014 Q4 | -351.62 Thousand CAD | -266.99% |
| 2014 Q3 | 210.56 Thousand CAD | 8.61% |
| 2014 Q1 | 116.16 Thousand CAD | -81.73% |
| 2014 Q2 | 193.87 Thousand CAD | 66.9% |
| 2014 FY | 168.97 Thousand CAD | 12162.63% |
| 2013 FY | 1378.00 CAD | 100.05% |
| 2013 Q2 | 169.57 Thousand CAD | 124.17% |
| 2013 Q1 | -701.66 Thousand CAD | -27.8% |
| 2013 Q3 | -102.27 Thousand CAD | -160.32% |
| 2013 Q4 | 635.74 Thousand CAD | 721.59% |
| 2012 Q1 | -517.74 Thousand CAD | -2.49% |
| 2012 FY | -2.63 Million CAD | -0.88% |
| 2012 Q2 | -609.42 Thousand CAD | -17.71% |
| 2012 Q4 | -549.04 Thousand CAD | 39.44% |
| 2012 Q3 | -906.58 Thousand CAD | -48.76% |
| 2011 Q3 | -745.15 Thousand CAD | -18.45% |
| 2011 Q4 | -505.14 Thousand CAD | 32.21% |
| 2011 FY | -2.61 Million CAD | -2.97% |
| 2011 Q1 | -734.36 Thousand CAD | -2571.51% |
| 2011 Q2 | -629.08 Thousand CAD | 14.34% |
| 2010 Q1 | -740.03 Thousand CAD | -3.4% |
| 2010 Q3 | -1.25 Million CAD | -117.29% |
| 2010 Q2 | -576.17 Thousand CAD | 22.14% |
| 2010 FY | -2.53 Million CAD | -2.17% |
| 2010 Q4 | 29.71 Thousand CAD | 102.37% |
| 2009 Q3 | -672.36 Thousand CAD | -31.11% |
| 2009 Q4 | -715.66 Thousand CAD | -6.44% |
| 2009 FY | -2.48 Million CAD | 32.26% |
| 2009 Q2 | -512.83 Thousand CAD | 12.14% |
| 2009 Q1 | -583.66 Thousand CAD | -32.62% |
| 2008 FY | -3.66 Million CAD | -35.26% |
| 2008 Q4 | -440.11 Thousand CAD | 53.43% |
| 2008 Q1 | -1.01 Million CAD | -24.41% |
| 2008 Q2 | -1.33 Million CAD | -31.33% |
| 2008 Q3 | -945.11 Thousand CAD | 28.94% |
| 2007 Q4 | -814 Thousand CAD | 13.46% |
| 2007 FY | -2.71 Million CAD | -29.63% |
| 2007 Q3 | -940.62 Thousand CAD | -98.01% |
| 2007 Q2 | -475.05 Thousand CAD | 1.47% |
| 2007 Q1 | -482.12 Thousand CAD | 67.33% |
| 2006 FY | -2.09 Million CAD | -1766.6% |
| 2006 Q1 | -106.05 Thousand CAD | 10.27% |
| 2006 Q4 | -1.47 Million CAD | -532.01% |
| 2006 Q2 | -276.9 Thousand CAD | -161.1% |
| 2006 Q3 | -233.47 Thousand CAD | 15.68% |
| 2005 Q2 | 132.23 Thousand CAD | 207.68% |
| 2005 Q1 | 42.97 Thousand CAD | -91.34% |
| 2005 Q3 | 66.56 Thousand CAD | -49.66% |
| 2005 Q4 | -118.19 Thousand CAD | -277.55% |
| 2005 FY | 125.52 Thousand CAD | 779.9% |
| 2004 Q3 | -276.13 Thousand CAD | -399.92% |
| 2004 Q1 | -150.37 Thousand CAD | -654.3% |
| 2004 Q2 | -55.23 Thousand CAD | 63.27% |
| 2004 FY | 14.26 Thousand CAD | 103.92% |
| 2004 Q4 | 496.01 Thousand CAD | 279.63% |
| 2003 Q3 | -101.76 Thousand CAD | -30.56% |
| 2003 Q2 | -77.95 Thousand CAD | 52.49% |
| 2003 Q1 | -164.05 Thousand CAD | -209.43% |
| 2003 Q4 | -19.93 Thousand CAD | 80.41% |
| 2003 FY | -363.7 Thousand CAD | -623.28% |
| 2002 Q3 | 76.02 Thousand CAD | 128.13% |
| 2002 FY | 69.5 Thousand CAD | -71.17% |
| 2002 Q2 | 33.32 Thousand CAD | 117.56% |
| 2002 Q1 | -189.75 Thousand CAD | -756.79% |
| 2002 Q4 | 149.91 Thousand CAD | 97.2% |
| 2001 Q2 | 105.61 Thousand CAD | 22.25% |
| 2001 Q4 | -22.14 Thousand CAD | -131.08% |
| 2001 Q3 | 71.26 Thousand CAD | -32.53% |
| 2001 Q1 | 86.39 Thousand CAD | 157.51% |
| 2001 FY | 241.12 Thousand CAD | 153.56% |
| 2000 Q4 | -150.22 Thousand CAD | 0.0% |
| 2000 Q3 | - CAD | 100.0% |
| 2000 Q2 | -300 Thousand CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 2000 FY | -450.22 Thousand CAD | 90.42% |
| 1999 Q3 | -300 Thousand CAD | 50.0% |
| 1999 Q4 | -3.4 Million CAD | -1033.33% |
| 1999 Q1 | -400 Thousand CAD | -300.0% |
| 1999 Q2 | -600 Thousand CAD | -50.0% |
| 1999 FY | -4.7 Million CAD | -123.81% |
| 1998 Q1 | -600 Thousand CAD | -200.0% |
| 1998 FY | -2.1 Million CAD | -2000.0% |
| 1998 Q4 | -100 Thousand CAD | 66.67% |
| 1998 Q3 | -300 Thousand CAD | 72.73% |
| 1998 Q2 | -1.1 Million CAD | -83.33% |
| 1997 FY | -100 Thousand CAD | 0.0% |
| 1997 Q3 | 100 Thousand CAD | 0.0% |
| 1997 Q2 | - CAD | 0.0% |
| 1997 Q4 | -200 Thousand CAD | -300.0% |
| 1997 Q1 | - CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.17 Million USD | 98.755% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 98.936% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 98.342% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.075% |
| GB Sciences, Inc. | -1.36 Million USD | 97.1% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 98.695% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 82.693% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.895% |
| Zenith Capital Corp. | -10.59 Million USD | 99.627% |
| Agentix Corp. | -1.37 Million USD | 97.127% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 99.435% |
| Biomind Labs Inc. | -1.21 Million USD | 96.749% |
| ContraFect Corporation | -65.15 Million USD | 99.939% |
| CSL Limited | 2.64 Billion USD | 100.001% |
| CytoDyn Inc. | -49.84 Million USD | 99.921% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 97.974% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 93.757% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.937% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 90.497% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 97.831% |
| Regen BioPharma, Inc. | 1.02 Million USD | 103.858% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.061% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.95% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 98.18% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.947% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 98.635% |
| Mesoblast Limited | -87.95 Million USD | 99.955% |
| Marizyme, Inc. | -65.34 Million USD | 99.94% |
| Genus plc | 7.9 Million USD | 100.5% |
| Pharming Group N.V. | -10.54 Million USD | 99.626% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 99.554% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 97.714% |
| IMV Inc. | -36.48 Million USD | 99.892% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 99.51% |
| MultiCell Technologies, Inc. | -380.07 USD | -10288.35% |
| ONE Bio Corp. | 8.67 Million USD | 100.455% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.924% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 98.942% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 98.727% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 99.5% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -163.642% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 99.751% |
| Alpha Cognition Inc. | -13.77 Million USD | 99.713% |
| Enzolytics Inc. | -2.17 Million USD | 98.186% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.987% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 140.289% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 100.57% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.959% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 99.4% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 85.559% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 99.048% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 34.675% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 98.031% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 99.637% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 99.192% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.946% |
| Helix BioMedix, Inc. | -1.05 Million USD | 96.261% |
| EV Biologics, Inc. | -1.26 Million USD | 96.884% |
| Q BioMed Inc. | -2.05 Million USD | 98.076% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 98.966% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.934% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 99.535% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 99.321% |
| HST Global, Inc. | -146.21 Thousand USD | 72.996% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 97.043% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 97.75% |
| Halberd Corporation | -79.67 Thousand USD | 50.446% |
| Resverlogix Corp. | -3.61 Million USD | 98.906% |
| Cell Source, Inc. | -5.32 Million USD | 99.258% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 99.006% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | 99.384% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -69.878% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 99.172% |
| Kadimastem Ltd | -3.3 Million USD | 98.806% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 99.111% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 91.054% |
| LadRx Corporation | 400.44 Thousand USD | 109.86% |
| Regen BioPharma, Inc. | 1.02 Million USD | 103.858% |
| Affymax, Inc. | -14.42 Million USD | 99.726% |
| Itoco Inc. | -1.86 Million USD | 97.887% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 97.634% |
| Mobile Lads Corp. | -2.26 Million USD | 98.256% |
| International Stem Cell Corporation | -131 Thousand USD | 69.86% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | 99.078% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 50.042% |
| Qrons Inc. | -789.34 Thousand USD | 94.998% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 95.807% |
| SYBLEU INC | -180.3 Thousand USD | 78.102% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 98.109% |
| Rebus Holdings, Inc. | -1.02 Million USD | 96.129% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 97.552% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 27.25% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 98.44% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.918% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 98.132% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 94.944% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 98.754% |
| Neutra Corp. | -233.46 Thousand USD | 83.088% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 99.805% |
| PureTech Health plc | -65.69 Million USD | 99.94% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 99.814% |
| IXICO plc | -1.17 Million USD | 96.648% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 99.602% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.931% |
| CSL Limited | 2.64 Billion USD | 100.001% |
| Cellectis S.A. | -103.17 Million USD | 99.962% |